Andere Sprachen Orphazyme A/S

Aktien

Verzögert Nasdaq Copenhagen Andere Börsenplätze 09:59:03 29.04.2024			% 5 Tage	% 1. Jan.
976,8 ^DKK	-10,39 %		-2,81 %	-26,56 %

27.03.	Orphazyme A/S meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
21.02.	Orphazyme A/S (CPSE:ORPHA) hat eine zusätzliche unbekannte Minderheitsbeteiligung an CombiGene AB (publ) (OM:COMBI) erworben.	CI

STALICLA Appoints Dr. Thomas Blaettler, MD	12.04.
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
FDA Extends Review of Zevra's Arimoclomol by Three Months	04.03.
BioStock: Comments from Orphazyme on the investment in CombiGene	04.03.
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	21.02.
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	21.02.
Zevra Therapeutics Refiles Arimoclomol Application With FDA	27.12.
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	10.10.23
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)	28.09.23
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	12.09.23
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	12.09.23
Change in management	30.05.23
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO	30.05.23
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO	30.05.23
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	30.05.23
Major shareholder announcement	19.05.23
Major shareholder announcement	17.05.23
Resolutions passed at the Annual General Meeting	17.05.23
Changes to the Board of Directors	17.05.23
Changes to the Board of Directors	17.05.23

Keine Ergebnisse zu dieser Suche